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Abstract
Tuberculosis (TB) remains to be a serious health problem worldwide. There is an increased 
transmission of Mycobacterium tuberculosis strains with drug resistance, hence complicat‐
ing TB control. The deciphering of the M. tuberculosis genome, together with the imple‐
mentation of new molecular biology tools, has allowed the identification of changes in 
nucleic acid sequences with a functional impact. These mutations have become important 
in the design of early‐diagnostic kits to identify the resistance profile of M. tuberculosis. 
Since the conventional methods to determine the identity of M. tuberculosis strains based 
in cultures are laborious, time‐consuming and performed by specialized technicians, the 
result is generated until 4 months after receiving the samples. During this time, patients 
with TB are not adequately treated, and resistant strains may be transmitted to the rest of 
the population. In this chapter, we describe the most relevant mutations in genes associ‐
ated with drug resistance in M. tuberculosis, the analysis of gene expression to identify 
new markers of drug resistance strains, and the development of new antituberculosis 
drugs against drug‐resistant strains.
Keywords: Mycobacterium tuberculosis, drug resistance, mutations, gene expression, 
antituberculosis drugs
1. Introduction
Tuberculosis (TB) has remained a serious health problem since Mycobacterium tuberculosis, the main 
agent of this disease, infects about one third population. In 2015, 10.4 million cases of TB were esti‐
mated and, although only a small percentage (5–10%) develops the illness, its control has compli‐
cated due to the emergence of drug resistance strains [1]. Tuberculosis regiment treatment includes 
the first line drugs rifampicine, isoniazide, ethambutol and pyrazinamide and strains that develop 
resistance to the two more effective antituberculosis drugs, isoniazide and rifampicine, named 
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multidrug resistance strains [2, 3]. The resistance phenomenon in M. tuberculosis has been highly 
related to mutations in specific genes [4], and this association has been the base for the implemen‐
tation of rapid diagnostics kits [5] but unfortunately mutations do not explain completely the resis‐
tance in all cases [6, 7], suggesting that other mechanisms could be involved. New approaches to 
search new markers and mechanisms of resistance have been performed. One of these is the evalu‐
ation of changes in gene expression [8]. Together with the diagnostics of TB, the implementation 
of new schemes of treatments is necessary to restrict the transmission. The development of new 
drugs against drug resistance M. tuberculosis has resulted promissory to control TB [9].
2. Mutations that confer resistance in Mycobacterium tuberculosis
Although the rate of resistance to first and second line drugs in M. tuberculosis varies among 
countries, the resistance phenomenon has complicated the tuberculosis control worldwide. 
There two types of observed resistance in M. tuberculosis, one is the genetic resistance 
where mutations in genomic regions, on target genes, confer the capacity to avoid the drug 
effect; the second is the phenotypic resistance, where epigenomic modifications, including 
alteration of protein structures, generate resistance to drugs without mutation on DNA. 
Although the current knowledge of the molecular genetic basis of resistance to antituber‐
culosis drugs has advanced rapidly the last years [10], there are unknown mechanisms 
in how bacilli is able to resist to drugs. Identification of clinical isolates with resistance 
to antituberculosis drugs would facilitate the timely and accurate diagnosis to initiate an 
appropriate treatment.
Many works have revealed, using microbiological and clinical data, mutational events in clin‐
ical isolates from patients with tuberculosis. Multidrug resistance appears to result from the 
sequential acquisition of mutations. Possible reasons for the acquisition of mutations include 
inadequate prescription and delivery of chemotherapy, poor compliance, or an insufficient 
number of active drugs in the treatment regimen [11]. Mutations or combinations of muta‐
tions have been found in strains displaying single or multidrug resistance. Here, we summa‐
rized the most common mutation found in clinical isolates that confer resistance to the first 
and second line antituberculosis drugs (Table 1).
2.1. Isoniazid
Due to its properties as a bactericidal drug, isoniazid has been widely used as the first line 
drug in the treatment against M. tuberculosis complex members. Mutations on katG and mabA‐
InhA genes have repeatedly been associated with isoniazid resistance [10] (Table 1). In the 
case of katG, the most common of mutation is S315, which is present in 50–95% of isoniazid 
resistant clinical isolates [12]. The occurrence of mutations is also observed in the promoter 
region of mabA/inhA. Mutations in the inhA promoter can also confer cross‐resistance to ethi‐
onamide [13]. There are other genes as ahpC, kasA, and ndh, encoding for alkyl hydroper‐
oxidase reductase, β‐ketoacyl‐ACP synthase, and NADH dehydrogenase, respectively, which 
have also been associated with isoniazid resistance.
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Drugs MIC (µg/mL) Drug mode of  
action
Gene Target enzyme Frequency of 
mutations (%) 
associated with 
resistance
Isoniazide 0.02–0.2 Inhibits mycolic  
acid synthesis and 
other multiple  
effects
katG Catalase peroxidase 30–60
InhA Fatty acid enoyl  
acyl carrier protein  
reductase A
70–80
ahpC Alkyl hydroperoxidase  
reductase
Not known
kasA β‐ketoacyl‐ACP  
synthase
Not known
ndh NADH dehydrogenase 9.5
Rifampicin 0.05–1 Inhibits RNA  
synthesis
rpoB β subunit of RNA  
polymerase
95
Streptomycin 2–8 Inhibits protein  
synthesis
rpsL Ribosomal protein S12 65–67
rrs 16S rRNA
gidB 7‐Methylguanosine  
methyltransferase
33
Ethambutol 1–5 Inhibits 
arabinogalactan  
synthesis
embCAB Arabinosyl transferase 70–90
Pyrazinamide 16–100 Disrupts 
plasmamembrane  
and energy  
metabolism  
(inhibits  
pantothenate and  
CoA synthesis)
pncA Pyrazinamidase >70
IS6110 
insertion
Not known
Fluoroquinolones 0.5–2.5 Introduces  
negative  
supercoils in  
DNA molecules
gyrA DNA gyrase 42‐85
gyrB
Kanamycin/
Amikacin
2–4 Inhibits protein  
synthesis
rrs 16S rRNA >60
Capreomycin/
Viomycin
2–4 Inhibits protein  
synthesis
rrs 16S rRNA 40‐100
tlyA rRNA  
methyltransferase
80
Ethionamide 2.5–10 Disrupts cell  
wall biosynthesis  
by inhibition  
of mycolic acid  
synthesis
InhA Fatty acid enoyl  
acyl carrier protein  
reductase A
>60
ethA Flavin monooxygenase >60
ethR Transcriptional  
repressor
Not known
Data taken and modified from [16] and [17].
Table 1. Genes associated with resistance to various anti‐TB drugs.
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2.2. Rifampicin
Rifampicin is highly bactericidal for M.tuberculosis, where this drug is able to bind to the β 
subunit of RNA polymerase, and this event induces hydroxyl radical formation in susceptible 
mycobacteria [14]. Resistance to rifampicin is acquired by mutations in a region of the 81‐bp 
region of the rpoB gene, encoding the β subunit of RNA polymerase, and these mutations 
have been found in ∼96% of rifampicin‐resistant clinical isolates. The most frequent muta‐
tions are located in positions 516, 526, and 531. Also, there is evidence that mutations in the 
rpoB gene generate cross‐resistance to rifamycins [15]. It is important to mention that not all 
mutations in rpoB are associated with rifampicin resistance [16].
2.3. Streptomycin
It has been considered as a second line antituberculosis drug, which binds to the 30S subunit 
of the ribosome and blocks protein synthesis. The resistance is provoked by mutations in the 
rpsL gene, which encoded the S12 protein, and the rrs gene, which encoded the 16S rRNA. 
The mutations in both genes are the main mechanism of streptomycin resistance, and it has 
been found in 65–67% of resistant clinical isolates [16]. There is another gene, gidB, involved in 
streptomycin resistance. This gene encoded a 7‐methylguanosine (m(7)G) methyltransferase, 
and mutations have been found in 33% of clinical isolates resistant to streptomycin.
2.4. Ethambutol
Ethambutol has a target, the inhibition of the enzyme arabinosyl transferase, which is involved 
in the biosynthesis of cell wall arabinogalactan. The enzyme is encoded by the embB gene, 
harboured in the embCAB operon, and mutation in this gene is related to ethambutol resis‐
tance. The most frequent mutation found in the embB gene is located in codon 306. More than 
68% of resistant clinical isolates have mutations in the embB gene [16].
2.5. Pyrazinamide
This pro‐drug is converted to its active form, pyrazinoic acid, and it only kills non‐growing 
persistent bacteria. The mutations of the pncA gene are scattered along this genomic region, 
and it is the main mechanism of pyrazinamide resistance. The majority of pyrazinamide‐
resistant clinical isolates (72–99%) have showed mutations on the pncA gene sequence. Due 
to a high correlation between mutations and pyrazinamide resistance, it has been suggested 
that the use of mutations to predict the resistance profile to pyrazinamide; however, there are 
silent mutations that do not confer resistance [16].
2.6. Fluoroquinolones
Fluoroquinolones are able to inhibit the activity of DNA gyrase. When the activity of DNA 
gyrase is affected, the chromosomal DNA acquires a supercoiled conformation [17]. Then, 
mutations on gyrA, encoding DNA gyrase, are strongly associated with fluoroquinolone 
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resistance. There are many reports where mutations located in the gyrA region are present in 
42–85% of clinical isolates resistant to fluoroquinolones (Louw et al., 2009). Also, mutations on 
the gyrB gene have also been associated with fluoroquinolone resistance, where 3% of clinical 
isolates harbor the mutation in this gene. The most common mutations of the gyrA gene are 
located in codons 90, 91 and 94 [16].
2.7. Amikacin/kanamycin
Amikacin and kanamycin are considered as second‐line antituberculosis drugs. It has been 
identified that the rrs gene as the target of action of these drugs; however, the molecular 
mechanisms that confer resistance are focused to inhibition of protein synthesis [18]. About 
60% of the clinical isolates resistant to amikacin/kanamycin have mutations on the rrs gene 
[17]. The most common mutations are located at the position 1400 of the rrs gene, which causes 
high‐level resistance these drugs.
2.8. Ethionamide
This prodrug requires to be activated by the mono‐oxygenase EtaA/EthA. It has been 
described as the only bactericidal agent against M. tuberculosis. Ethionamide inhibits 
mycolic acid synthesis. Mutations in inhA also confer resistance to ethionamide. Frequency 
of mutations on etaA/ethA, ethR, and inhA genes in clinical isolates resistant to ethionamide 
reaches 60% [16].
Mutations described in M. tuberculosis have led to the implementation of rapid molecular 
diagnostic kits with the aim to diagnose TB and detect drug resistance in a shorter period 
compared to drug susceptibility testing based on the culture of the microorganism [19].
Within the rapid methods approved by the WHO, there are real‐time PCR‐based assays, 
as Xpert MTB/RIF, the line probe assays Genotype MTBDRplus and Genotype MTBDRsl. 
The XpertMTB/RIF tests allow M. tuberculosis detection as well as resistance to rifampicine. 
A multicenter study in which 6648 patients were evaluated, the Xpert MTB/RIF test allowed 
the detection of 90.3% of the TB confirmed cases based on culture, as well as 67.1% of the TB 
cases diagnosed by microscopy. For detection of rifampicine resistance, a sensitivity of 94.4% 
and specificity of 98.3% were reported, and an indeterminate rate of 2.4%, which was lower 
than that of culture diagnose with 4.6% [20]. On the other hand, the Genotype MTBDRplus 
allows detection of resistance for the first line drugs, while Genotype MTBDRsl detects resis‐
tance to the second line drugs. A meta‐analysis of Genotype MTBDRplus reported a pooled 
sensitivity of 0.91, 0.96, and 0.91 and a pooled specificity of 0.99, 0.98 and 0.99 for the detec‐
tion of isoniazide‐, rifampicine‐, and multidrug‐resistance, respectively. Both, sensitivity and 
specificity settings have 95% confidence intervals [21]. Finally, in a multicenter study realized 
in 2012, the accuracy of the Genotype MTBDRsl was evaluated in 200 M. Tuberculosis isolates; 
in this study, the sensitivity reported was between 77.3 and 92.3% for the detection of resis‐
tance to fluoroquinolones, ethambutol, amikacin, and capreomycin while for kanamycin was 
42.7 and 22.6% for XDR detection; the specificity was 82% for all drugs [22].
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3. Searching for new markers to identify drug resistance of  
Mycobacterium tuberculosis
In the understanding and linking‐up of genetic associations with the drug resistance phe‐
notype in M. tuberculosis, mutations in specific genes have been the most common associa‐
tion as previously described; nevertheless, not all resistant M. tuberculosis strains have the 
related mutations previously reported suggesting that other mechanisms could be involved 
in this  phenomenon [6, 23, 24]. For this purpose, the expression level of some genes has been 
studied. One of them is efflux pump genes, these are important elements that play a role 
in the extrusion of drugs out of the cells conferring M. tuberculosis resistance to drugs [25]. 
The efflux pumps have been classified in super families: ATP‐binding cassette (ABC), major 
facilitator super‐family (MFS), resistance nodulation division (RND), small multidrug resis‐
tance (SMR), and multidrug and toxic‐compound extrusion (MATE) [23]. In M. tuberculosis, 
the efflux pumps consist of (a) 12 mycobacterial large membrane proteins (MmpL) belonging 
to RND‐type transporters [26], (b) 37 ABC transporters (26 complete and 11 incomplete) from 
which 21 are putative exporters which include antibiotic transporters that represent the 2.5% 
of the genome [27, 28] and (c) 16 putative MFS drug efflux pumps [29]. Some findings have 
reported efflux pump genes to be overexpressed in drug resistance M. tuberculosis strains 
(Table 2) [25, 30‐32]. The importance of efflux pumps involved in drug resistance has led to 
suggest the analysis of the implementations of a combined therapy of antituberculosis drugs 
together with efflux pump inhibitors [23].
Locus Symbola Gene namea Drug‐resistant 
phenotype
References
Rv2688c Antibiotic‐transport ATP‐binding 
protein ABC transporter
XDR [32]
Rv1634 Drug efflux membrane protein XDR [32]
Rv2936 drrA Daunorubicin‐dim‐transport ATP‐
binding protein ABC transporter 
drrA
XDR [32]
[30]
Rv2937 drrB Daunorubicin‐dim‐transport 
membrane protein ABC transporter 
drrB
XDR [32]
[30]
Rv0820 phoT Phosphate‐transport ATP‐binding 
protein ABC transporter phoT
XDR [31]
Rv2136c uppP Conserved membrane protein MDR [25]
Rv2846c efpA Membrane efflux protein efpA MDR [30]
Rv0849 Conserved membrane transport 
protein
MDR [30]
Rv1250 MDR [30]
Rv1410 Aminoglycosides/tetracycline‐
transport membrane protein
MDR [30]
Rv1634 Drug efflux membrane protein MDR [30]
Rv2994 Conserved membrane protein MDR [30]
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Furthermore, studies in drug resistance strains have reported other genes as differentially 
expressed between sensitive and drug‐resistant strains. Functional categories of these genes 
are among others, stress response and translation (Table 3). On the other hand, expression 
of intergenic regions (IGs) has also been associated with a drug resistance phenomenon in 
M. tuberculosis [8, 25, 31], suggesting that an additional analysis is necessary to evaluate and 
confirm the contribution of these regions in drug resistance.
With the aim to demonstrate the resistance association between the level of expression of 
some genes and drug resistance, assays using recombinant strains of M. tuberculosis as well 
as other Mycobacterium strains treated with different drugs and/or overexpressing genes 
of interest have been analyzed [25, 33‐35]. The new findings related to differences of gene 
basal expression between susceptible and resistant M. tuberculosis strains can contribute to 
identify newly genetic drug‐resistant markers that could contribute in the early diagnosis of 
drug‐resistant tuberculosis, which could be applied in the establishment of a more efficient 
drug therapy [8, 30].
Locus Symbola Gene namea Drug‐resistant 
phenotype
References
Rv2333c stp Involved in transport of drug across 
the membrane (export)
MDR [30]
Rv2459 Conserved membrane transport 
protein
MDR [30]
aData obtained from TB database and/or TubercuList, XDR: extensively drug‐resistant.
Table 2. Overexpressed efflux pump genes in drug‐resistance Mycobacterium tuberculosis strains.
Locus Symbola Gene namea Expression level 
modification
Drug‐resistant 
phenotype
References
Rv1181 pks4 Polyketide beta‐ketoacyl synthase 
pks4
I XDR [31]
Rv1182 ppA3 Polyketide synthase associated 
protein papA3
I XDR [31]
Rv1184c Hypothetical exported protein I XDR [31]
Rv0826 Conserved hypothetical protein I XDR [31]
Rv1483 fabG1 3‐oxoacyl‐[acyl‐carrier protein] 
reductase fabG1
I XDR [31]
Rv1592c Conserved hypothetical protein I XDR [31]
Rv1623c cydA Membrane cytochrome D 
ubiquinol oxidase subunit I cydA
I XDR [31]
Rv2585c Conserved lipoprotein I XDR [31]
Rv2621 Transcriptional regulator I XDR [31]
Rv3269 Conserved hypothetical protein I XDR [31]
Rv0287 esxG Esat‐6 like protein esxG I MDR [8]
Rv0288 esxH Low molecular weight protein 
antigen 7 esxH
I MDR [8]
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4. Development of new drugs against Mycobacterium tuberculosis drug 
resistance strains
Even though tuberculosis antibiotic treatment therapy is described, drug resistance in 
M. tuberculosis complicates the TB control. In 2015, 480,000 MDR tuberculosis cases were esti‐
mated and, in addition, 100,000 more cases were added which had resistance to rifampicin 
[1], these cases are more likely to develop multi‐drug resistance. Drug‐resistant TB has led 
to the implementation of new therapeutic regimens involving second line drugs, once drug 
susceptibility testing results are available [36].
Drug therapy for a patient infected with a susceptible M. tuberculosis strain lasts 6 months 
with diverse combinations of the first‐line drugs rifampicine, isoniazid, ethambuthol, and 
pyrazinamide, while treatment therapy for a patient with DR tuberculosis can last up to 
20 months and include a fluoroquinolone, an injectable aminoglycoside plus an oral bacterio‐
static second line drug and a first line drug (for details consult D’Ambrosio et al. [36]).
Because the problem of resistant tuberculosis is increasing, searching for new drugs contin‐
ues with the aim of improving the therapeutic regimens currently used, shorten treatment 
duration in addition to find more effective drugs for latent TB and drug‐resistant strains. The 
development of new antituberculosis drugs implicates the following stages: basic research, 
discovery of new antituberculosis compounds or drugs, preclinical and clinical studies con‐
formed by phases I, II, and III to finally get to the technology transfer; all these processes 
entail long periods of time [37]. In this continuous search for better antituberculosis drugs, 
many natural, semi‐synthetic, and synthetic compounds have been evaluated in vitro and 
in vivo. We will mention some new drugs that are based on the structure of first line drugs, 
among which some analogues have been described with activity against sensitive and drug 
resistant M. tuberculosis strains. Thereby based on ethambutol, some of the novel described 
Locus Symbola Gene namea Expression level 
modification
Drug‐resistant 
phenotype
References
Rv1037c esxI Esat‐6 like protein esxI I MDR [8]
Rv1642 rpmI 50S ribosomal protein L35 rpmI I MDR [8]
Rv1630 rpsA 30S ribosomal protein S1 rpsA I MDR [8]
Rv3487c lipF Esterase/lipase lipF R MDR [8]
Rv3418c groES 10 kda chaperonin groES R MDR [8]
Rv1161 narG Respiratory nitrate reductase alpha 
chain narG
R MDR [8]
Rv1819c Drugs‐transport transmembrane 
ATP‐binding protein ABC 
transporter
R MDR [25]
aData obtained from TB database. XDR: extensively drug‐resistant, MDR: multidrug‐resistant, I: gene with induced 
expression in the resistant strain analyzed, R: gene with repressed expression in the resistant strain analyzed.
Table 3. Differential expressed genes in drug‐resistance Mycobacterium tuberculosis strains.
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compounds comprise SQ109 and analogues based on carbamate prodrugs [38], S2824 and 
analogues with a homopiperazine ring [39], 1,2 diamines [40], ferrocenyl compounds [41] 
and dihydrosphingosine‐ethambutol analogues [9]. Within pyrazinamide analogues, it has 
been described POEs (pyrazinoic acid esters) and 5‐Cl‐substituted pyrazinoic acid deriva‐
tives [42]. However, it is necessary to consider the adverse effects of these compounds. For 
isoniazide‐based compounds, there has been reported aromatic and heterocyclic aldehydes 
containing electron‐withdrawing or donating groups [43], and rifampicin has been described 
within the rifamycins as well as among others as rifabutin, rifapnetine, rifalazil, and rifam‐
etane [44].
As general conclusion, although mutations are commonly associated with drug resistance in 
M. tuberculosis, other studies are necessary to discover genetic markers that support the early 
diagnostic of drug resistance in strains that enable the establishment of optimized therapeutic 
schemes limiting their transmission.
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